Cancerous tumors start small and grow larger over time, adding defensive mechanisms that make them resistant to treatments and more deadly. So, to find cancers at the earlier stages when they can be treated more effectively, clinicians must have the ability to detect smaller tumors. That’s why Imagion Biosystems is working hard to develop MagSense™ superparamagnetic relaxometry (SPMR) technology.
The chart below illustrates the theoretical relative limits of detection of SPMR vs conventional imaging methods (CT and MRI):
We believe that MagSense technology could have the ability to accurately detect a roughly spherical tumor of approximately one millimeter diameter. Relative to conventional imaging methods, this could allow diagnosis to occur significantly earlier. And save lives.